Showing 793 articles by Liz Highleyman

Filters Author: Liz Highleyman

Liz is a medical journalist specialising in HIV, hepatitis and cancer, and science editor for POZ magazine. She has contributed conference news reporting for aidsmap since 2004. 

X  |  Bluesky

Antibody-based treatment

Broadly neutralising antibodies plus immune modulator may delay HIV rebound

News
21 July 2025
Injectable & long-acting PrEP

Once-monthly oral PrEP moves into late-stage trials

News
17 July 2025
Sexually transmitted infections prevention

Resistance is a growing concern amid rising use of doxyPEP

News
16 July 2025
Hepatitis & HIV

What are fibrosis and cirrhosis?

About HIV
May 2025
Weight gain & lipodystrophy

Semaglutide may slow ageing, improve cognition and curb alcohol use

News
28 April 2025
Health problems & ageing

CMV antiviral may reduce inflammation and improve immune function in people with HIV

News
21 March 2025
Antibody-based treatment

Broadly neutralising antibody N6LS could be part of long-acting HIV treatment

News
17 March 2025
Injectable & long-acting PrEP

Once-yearly PrEP moves closer: experimental lenacapavir formulations show promise

News
17 March 2025
Injectable & long-acting HIV treatment

Lenacapavir plus broadly neutralising antibodies could be twice-yearly HIV treatment

News
12 March 2025
The search for a cure

Two more people with HIV may be cured after stem cell transplants

News
12 March 2025
The search for an HIV prevention vaccine

Is germline targeting the future of HIV vaccine development?

News
12 June 2024
The search for a cure

CRISPR gene therapy EBT-101 does not prevent HIV viral rebound

News
14 May 2024
Injectable & long-acting HIV treatment

Long-acting injectables can be a good option for people with adherence challenges

News
20 March 2024
Liver disease

Semaglutide improves fatty liver disease and inflammation in people with HIV

News
13 March 2024
Injectable & long-acting PrEP

Ultra-long-acting cabotegravir could be taken three times a year for HIV PrEP and treatment

News
12 March 2024
The search for a cure

Some children who start antiretrovirals very early may control HIV after stopping treatment

News
7 March 2024
New & experimental HIV treatments

Islatravir plus lenacapavir could be the first once-weekly oral HIV treatment

News
6 March 2024
New & experimental HIV treatments

Broadly neutralising antibodies may be partners for long-acting antiretrovirals

News
6 March 2024
Sexually transmitted infections prevention

Sexually transmitted infections in San Francisco have fallen since doxyPEP roll-out

News
5 March 2024
Injectable & long-acting HIV treatment

Long-acting injectables may be better than daily pills for people with adherence challenges

News
23 February 2024
Sexually transmitted infections prevention

DoxyPEP did not reduce STIs among women, probably due to low adherence

News
15 January 2024
Mpox

High death rate in mpox outbreak in the Democratic Republic of Congo

News
30 November 2023
Weight gain & lipodystrophy

New weight-loss drugs appear safe and effective for people living with HIV

News
16 November 2023
Bad science & bogus treatments

CRISPR gene therapy appears safe, but claims of an imminent HIV cure are premature

News
3 November 2023